Table 1.
Patient | Sex | Age (years) | Disease at diagnosis | Tumor site | Follow-up time (years) |
---|---|---|---|---|---|
1 | Male | 8.1 | Localized | Femur | 2.9 |
2 | Male | 21.3 | Localized | Scapula | 0.8 |
3 | Female | 17.8 | Localized | Femur | 2.1 |
4 | Male | 16.3 | Localized | Femur | 1.0 |
5 | Male | 13.1 | Localized | Femur | 1.3 |
6 | Male | 9.3 | Localized | Tibia | 2.8 |
7 | Female | 14.2 | Localized | Tibia | 2.1 |
8 | Male | 12.2 | Localized | Femur | 2.0 |
9 | Female | 15.9 | Localized | Femur | 2.1 |
10 | Female | 11.9 | Localized | Femur | 2.0 |
11 | Male | 12.1 | Localized | Femur | 1.9 |
12 | Male | 16.6 | Localized | Humerus | 2.3 |
13 | Female | 7.5 | Localized | Femur | 0.7 |
14 | Female | 12.1 | Localized | Tibia | 2.5 |
15 | Female | 16.9 | Localized | Humerus | 2.0 |
16 | Male | 19.1 | Localized | Humerus | 2.0 |
17 | Female | 16.2 | Localized | Tibia | 2.0 |
18 | Female | 17.1 | Localized | Femur | 2.4 |
19 | Male | 13.9 | Localized | Femur | 1.1 |
20 | Male | 22.7 | Metastatic | Tibia | 1.0 |
21 | Female | 9.0 | Metastatic | Femur | 1.3 |
22 | Male | 10.0 | Metastatic | Femur | 1.2 |
23 | Female | 14.3 | Metastatic | Humerus | 1.0 |
24 | Male | 12.7 | Metastatic | Femur | 0.7 |
25 | Male | 8.2 | Metastatic | Other | 2.2 |
26 | Male | 14.9 | Metastatic | Femur | 2.0 |
27 | Female | 16.4 | Metastatic | Femur | 1.9 |
28 | Female | 17.1 | Metastatic | Femur | 1.6 |
29 | Male | 12.7 | Metastatic | Tibia | 1.9 |
30 | Male | 4.4 | Metastatic | Tibia | 2.0 |
31 | Female | 17.3 | Metastatic | Scapula | 2.0 |
32 | Male | 11.4 | Metastatic | Femur | 2.0 |
33 | Male | 14.5 | Metastatic | Femur | 0.9 |
34 | Male | 15.5 | Metastatic | Femur | 1.0 |
35 | Male | 13.2 | Metastatic | Femur | 0.7 |
36 | Male | 11.6 | Metastatic | Femur | 0.5 |
37 | Female | 5.6 | Metastatic | Femur | 1.0 |
38 | Female | 7.7 | Metastatic | Femur | 1.2 |
39 | Female | 12.3 | Metastatic | Tibia | 1.0 |